Encapsulation and cardiac differentiation of hiPSCs in 3D PEG-fibrinogen hydrogels
The present invention relates to the production of cell cultures and tissues from undifferentiated pluripotent stem cells using three-dimensional biomimetic materials. The resultant cell cultures or tissues can be used in any of a number of protocols including testing chemicals, compounds, and drugs. Further, the methods and compositions of the present invention further provide viable cell sources and novel cell delivery platforms that allow for replacement of diseased tissue and engraftment of new cardiomyocytes from a readily available in vitro source. The present invention includes novel methods required for the successful production of cell cultures and tissues, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
1. A method of producing a three-dimensional cell culture or tissue comprising:
combining a population of pluripotent stem cells (PSCs) with a PEG-fibrinogen hydrogel material to form a biomimetic-PSC suspension;
treating said biomimetic-PSC suspension by cross-linking to produce a three-dimensional biomimetic-PSC microenvironment; and
culturing said biomimetic-PSC microenvironment to differentiate the PSCs into cardiac tissue.
2. The method of claim 1 wherein said treating said biomimetic-PSC suspension further comprises placing said biomimetic-PSC suspension into a mold prior to said cross-linking.
3. The method of claim 1 wherein said microenvironment is selected from the group consisting of microislands, cardiac discs, strings, macrotissues, and microspheres, and combinations thereof.
4. The method of claim 1 wherein said treating said biomimetic-PSC suspension to produce a three-dimensional biomimetic-PSC microenvironment comprises covalently cross-linking said biomimetic material.
5. The method of claim 4 wherein said covalently cross-linking said biomimetic material comprises photo-crosslinking.
6. The method of claim 5 wherein said biomimetic material comprises PEG-fibrinogen, an accelerator, and at least one photoinitiator component.
7. The method of claim 6 wherein said accelerator is triethanolamine (TEOA), and said at least one photoinitiator component comprising and Eosin Y.
8. The method of claim 1 wherein said PSCs are human induced PSCs (hiPSCs).
9. The method of claim 1 wherein said PSCs are differentiated into cardiomyocytes.
10. The method of claim 9 further comprising:
producing synchronously contracting, functional cardiac tissue from said cardiomyocytes.